XDWH:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI World Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 49.26

Change

-1.13 (-2.24)%

Market Cap

USD 2.60B

Volume

440.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-7.14 (-1.30%)

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.71 (-1.40%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.68 (-1.22%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.22 (-1.46%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

-0.87 (-0.89%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.70 (-0.74%)

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

-0.09 (-1.16%)

USD 41.48B
0ZC:F Zscaler Inc

+5.34 (+2.98%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.71%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-1.44 (-1.15%)

USD 24.77B

ETFs Containing XDWH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.36% 63% D 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.36% 62% D 58% F
Trailing 12 Months  
Capital Gain -0.74% 27% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.74% 24% F 40% F
Trailing 5 Years  
Capital Gain 71.52% 54% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.52% 54% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 10.64% 69% C- 65% D
Dividend Return 10.64% 67% D+ 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.90% 72% C 93% A
Risk Adjusted Return 119.52% 97% N/A 97% N/A
Market Capitalization 2.60B 87% B+ 69% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike